Moreover, in a study of ten patients with nickel contact allergies, secukinumab resulted in a slight decrease in the clinical scoring of nickel patch test reactions but not in inflammation or skin thickness, indicating that anti-IL-17 may not be a viable treatment for allergic contact dermatitis [61]. Here, IL17A is linked to allergic contact dermatitis.